Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 18/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 13/20 | 0.73 |
| ▸ | SYK | P43405 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057428 | 0.85 | AURKA (1.00) | AURKAAURKBSYK | |
| SCHEMBL4066956 | 0.77 | AURKA (0.62) | AURKAAURKBTP53KDM4EMAPT | |
| SCHEMBL4059036 | 0.70 | AURKA (1.00) | AURKAAURKBSYK | |
| SCHEMBL4057805 | 0.69 | AURKA (1.00) | AURKAAURKBSYK | |
| SCHEMBL4056619 | 0.69 | AURKA (1.00) | AURKAAURKBSYK | |
| SCHEMBL4055721 | 0.69 | AURKA (0.84) | AURKAAURKBSYK | |
| SCHEMBL12430593 | 0.67 | AURKA (0.73) | AURKAAURKBKDM4EMAPT | |
| SCHEMBL4056738 | 0.67 | AURKA (0.76) | AURKAAURKBSYK | |
| SCHEMBL4055241 | 0.67 | AURKA (0.70) | AURKAAURKBSYKKDM4E | |
| SCHEMBL3963930 | 0.66 | KMT2A (0.43) | AURKAAURKBTP53KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016130460-A9 | PHTHALAZINONE PYRAZOLE DERIVATIVES FOR TREATING RETINAL DEGENERATIVE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-09-15 | — | — | WO | claimed |
| WO-2016130460-A2 | PHTHALAZINONE PYRAZOLE DERIVATIVES FOR TREATING RETINAL DEGENERATIVE DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-08-18 | — | — | WO | claimed |
| CN-101027290-B | 2, 3-phthalazinone derivatives as AURORA-a kinase inhibitors | HOFFMANN LA ROCHE | 2010-05-12 | — | — | CN | claimed |
| EP-1794148-B1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | claimed |
| CN-101027290-A | Novel 2,3-phthalazinone derivatives, as AURORA-A kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | CN | claimed |
| US-7226923-B2 | Phthalazinone derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | claimed |
| US-20060089359-A1 | Phthalazinone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-27 | — | — | US | claimed |
| CN-101027290-B | 2, 3-phthalazinone derivatives as AURORA-a kinase inhibitors | HOFFMANN LA ROCHE | 2010-05-12 | — | — | CN | disclosed |
| EP-1794148-B1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-15 | — | — | EP | disclosed |
| CN-101405001-A | Methods of inhibiting BTK and SYK protein kinases | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | CN | disclosed |
| CN-101027290-A | Novel 2,3-phthalazinone derivatives, as AURORA-A kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2007-08-29 | — | — | CN | disclosed |
| EP-1794148-A1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-7226923-B2 | Phthalazinone derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060089359-A1 | Phthalazinone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-27 | — | — | US | disclosed |
| WO-2006032518-A1 | NOVEL PHTHALAZINONE DERIVATIVES, AS AURORA-A KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089359-A1 | Phthalazinone derivatives | SDHA, SDHB, CYP3A5 | AURKA 1585/4885AURKB 1484/4885SYK 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.